A Phase II, Open-Label, Multicenter Study of the Efficacy and Safety of Single-Agent Apomab in Patients With Advanced Chondrosarcoma.
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Drozitumab (Primary)
- Indications Chondrosarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 09 Oct 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov
- 25 Oct 2007 New trial record.